Rezolute Inc. (NV) (RZLT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Rezolute Inc. (NV) (NASDAQ: RZLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.95 (-4.13% 1D, market cap $398.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RZLT ranks #579 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RZLT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AVTX (Avalo Therapeutics Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $385.5M). Among the 5-stock peer group, RZLT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).
Per RZLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001509261), Rezolute Inc. (NV) generated $0 in revenue, -$74.4M in net income, and -$69.1M in free cash flow against $138.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 28% of 52W Range • RSI-14 at 50.6 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RZLT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.23) and Max Pain ($4.15) forces dealer call-delta covering toward $12.03.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Rezolute Inc. (NV) (RZLT) dropped -4.13% to $3.95, trading at 28% of its 52-week range ($1.07 – $11.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any fo
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refracto
Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label
The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism
Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting befor
The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities On track to report topline results for the Phase 3
Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regul
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congeni
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RZLT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RZLT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Rezolute Inc. (NV) (RZLT) ranks #579 by composite RQD confidence (38/100, grade D-) and #482 by equity capitalization ($398.5M). Within this direct 5-issuer industry benchmark cohort, RZLT leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. RZLT currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RZLT
ACTIVE
Rezolute Inc. (NV) | D- | 38/100 | — | — | -35.0% | -4.13% | $398.5M | Benchmark Subject |
| AVTX Avalo Therapeutics Inc. | E | 17/100 | — | — | -35.0% | -3.63% | $399.0M | /avtx-vs-rzlt → |
| CAPR Capricor Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.77% | $385.5M | /capr-vs-rzlt → |
| ALT Altimmune Inc. | E | 22/100 | — | — | -34.7% | -4.67% | $416.3M | /alt-vs-rzlt → |
| ASMB Assembly Biosciences Inc. | E | 16/100 | — | — | -6.5% | -3.50% | $424.7M | /asmb-vs-rzlt → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Rezolute Inc. (NV) (RZLT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$74.4M, operating cash flow of -$69.1M, and free cash flow of -$69.1M (-20.4% YoY). On the balance sheet, RZLT closed FY2025 with $138.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$74.4M | -$69.1M | -$69.1M | $138.6M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$68.5M | -$57.4M | -$57.4M | $112.0M | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$51.8M | -$44.5M | -$44.5M | — | — |
As of 2026-11-02, Rezolute Inc. (NV) (NASDAQ: RZLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.95 (-4.13% 1D, market cap $398.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RZLT ranks #579 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RZLT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AVTX (Avalo Therapeutics Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $399.0M) and CAPR (Capricor Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $385.5M). Among the 5-stock peer group, RZLT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).
Per RZLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001509261), Rezolute Inc. (NV) generated $0 in revenue, -$74.4M in net income, and -$69.1M in free cash flow against $138.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RZLT last traded at $3.95 (-4.13% on volume of 779,261 shares), positioning the stock -6.62% below its 50-day simple moving average ($4.23) and +1.54% above its 200-day simple moving average ($3.89). Across its 52-week range of $1.07 to $11.46, RZLT sits at the 27.7% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.46 to $4.44).
Why RZLT Stock dropped -4.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, RZLT scores 38 out of 100, a D- grade with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC of -35%; FCF yield of -17.33%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are the cash engine and insider conviction. Negative ROIC and negative FCF yield indicate the business is consuming capital rather than generating it, so any upside case depends on external funding or a future commercial inflection not visible in the source data. The Piotroski F-Score of 2/9 is weak and the Altman Z of 2.5 sits in a range that warrants scrutiny of solvency. Institutional flow receives moderate credit, but the insider pillar is the lowest-scoring signal. The Beta of 1.0 means the stock is expected to move with the market, so macro regime fit neither adds nor removes significant risk on its own. The overall profile points to valuation tradeoffs skewed toward downside unless the cash burn narrows.
Rezolute Inc. (NV) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, its market capitalization is $0.4B. Per the SEC financials, reported revenue for FY 2025, FY 2024, and FY 2023 is $0.0M in each period, so the source data does not show a revenue-generating product base. Customer and monetization details are not available in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-79.9M | $-74.4M | N/A | $-69.1M | $11.9M | N/A |
| FY 2024 | $0.0M | $-70.4M | $-68.5M | N/A | $-57.4M | $8.9M | N/A |
| FY 2023 | $0.0M | $-56.0M | $-51.8M | N/A | $-44.5M | N/A | N/A |
Per the SEC financials, operating losses widened from $-56.0M in FY 2023 to $-79.9M in FY 2025, and free cash flow was negative in every reported period. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5. Cash rose from $8.9M to $11.9M across the two most recent periods, but the source data does not show a debt figure to assess liquidity against the burn rate.
Real-time company headlines, analyst actions, and sector developments for Rezolute Inc. (NV) (RZLT) • Click "Debate This Headline" to argue it in the Roar Pit below
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any fo
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refracto
Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label
The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism
Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting befor
The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities On track to report topline results for the Phase 3
Healthcare stocks were lower late Wednesday afternoon with the NYSE Healthcare Index and the State S
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regul
Welcome to the RZLT (Rezolute Inc. (NV)) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on RZLT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Rezolute Inc. (NV) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on RZLT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.12 (52-wk range $1.07 - $11.46), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).